New insight into RA patient priorities and motivators for clinical…
The News Review:
- New insight into RA patient priorities and motivators for clinical…
- Quintiles may buy British software company
- Capros Unleashes the Synergy of Superfruits
New insight into RA patient priorities and motivators for clinical…
EurekAlert – EurekAlert (press release) – Jun 13, 2008
Reassuringly many of the aspects found to be important to patients are reflected in standard clinical quality of life measures but RAID goes one step further in ensuring the experience of living with RA is fully taken into consideration when assessing the effectiveness of interventions. ” Patient motivation in clinical trial enrolmentThe second initiative is a study that sought to understand patient perspectives and motivators for participating in clinical trials in order to help encourage active participation in future research. 60 RA patients attending various rheumatology departments in Romania were interviewed with a questionnaire exploring possible reasons for participating in clinical research as well as aspects of clinical trials that were perceived drawbacks to enrollment. Data were analysed using SPSS 13. 0 (a statistical and data management package for analysts and researchers) and one way Anova (an analysis of variance). The study showed that the two reasons that patients considered the most important when agreeing to participate in clinical trials were potential benefits to themselves (90%) or other patients (77%) and to enhance knowledge and understanding of RA (83%).
Quintiles may buy British software company
News & bserver – Jun 13, 2008
comp –> ClinPhone makes software that helps select people for drug tests and for the data collected from the tests. “Quintiles believes that the operations of ClinPhone are a strategic fit with Quintiles’ clinical research capabilities” a statement said. The company confirmed that discussions with ClinPhone’s board of directors are ongoing and may lead to a counterbid. Quintiles has been privately owned since a $1. 75 billion management-led buyout. The company generated more than $2 billion in revenue last year.
Capros Unleashes the Synergy of Superfruits
FreshPlaza – Jun 13, 2008
Appreciable synergism between the juices extracted from the edible parts was observed. Further studies showed that Capros® fortification in commercial pomegranate juices or concentrates improve the antioxidant potential of the juice. Capros® is made by Natreon Inc. which brings together the powers of ancient medicine with the support and backing of modern science and clinical research. As a leading research company dedicated to developing the novel compounds revered in Ayurvedic medicine an ancient form of treatment practiced daily by millions of individuals worldwide Natreon Inc. is committed to using modern technology and science to support these safe and effective ancient treatments for today’s contemporary world.
Written by admin on June 13th, 2008 with
no comments.
Read more articles on News.